Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13066033 | 0.89 | TSHR (0.49) | MEN1KMT2AALDH1A1MAPK1CYP1A2 | |
| SCHEMBL26938985 | 0.89 | TSHR (0.49) | MEN1KMT2AALDH1A1MAPK1CYP1A2 | |
| SCHEMBL9917383 | 0.88 | HRH3 (0.51) | MEN1KMT2AALDH1A1MAPK1CYP1A2 | |
| SCHEMBL9136935 | 0.88 | MEN1 (0.43) | MEN1KMT2AALDH1A1MAPK1CYP1A2 | |
| SCHEMBL10100370 | 0.86 | ALDH1A1 (0.51) | MEN1KMT2AALDH1A1MAPK1CYP1A2 | |
| SCHEMBL20328707 | 0.86 | TSHR (0.43) | MEN1KMT2AALDH1A1MAPK1CYP1A2 | |
| SCHEMBL22296937 | 0.84 | KDM1A (0.42) | MAPK1CYP1A2SIGMAR1SMN1; SMN2 | |
| SCHEMBL12923488 | 0.84 | MEN1 (0.41) | MEN1KMT2AALDH1A1MAPK1CYP1A2 | |
| SCHEMBL17581960 | 0.84 | MEN1 (0.41) | MEN1KMT2AALDH1A1MAPK1CYP1A2 | |
| SCHEMBL28472338 | 0.84 | USP2 (0.45) | MEN1KMT2AALDH1A1MAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-23 | — | — | US | disclosed |
| WO-2023220046-A1 | TYK2 INHIBITORS | BIOGEN MA INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070254894-A1 | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation | KANE JOHN L JR | 2007-11-01 | — | — | US | disclosed |
| US-20070254894-A1 | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation | KANE JOHN L JR | 2007-11-01 | — | — | US | disclosed |
| US-7279489-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-7265129-B2 | Anti-infective biaryl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | MEN1 1230/4885KMT2A 3742/4885ALDH1A1 274/4885 |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | IDO2, IRF2BP2, IRF3 | MEN1 4705/4885KMT2A 1563/4885ALDH1A1 3628/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | MEN1 1514/4885KMT2A 4371/4885ALDH1A1 4236/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | MEN1 2978/4885KMT2A 2685/4885ALDH1A1 3576/4885 |
| US-20070254894-A1 | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation | MKI67, VEGFA, KDR | MEN1 3575/4885KMT2A 4653/4885ALDH1A1 1480/4885 |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | AXL, TYRO3, FLT3 | MEN1 3600/4885KMT2A 3149/4885ALDH1A1 4026/4885 |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | PCK1, PDK2, PDK1 | MEN1 3421/4885KMT2A 1195/4885ALDH1A1 1403/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | MEN1 221/4885KMT2A 1189/4885ALDH1A1 1158/4885 |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | MIF, MMP12, METAP1 | MEN1 951/4885KMT2A 1661/4885ALDH1A1 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.